Eur J Cancer: Effects of diabetes and metformin on recurrence risk and prognosis in colon cancer patients

Diabetes (DM) and metastatic colorectal (CRC)Increased risk of colorectal cancer is associated with worse prognosis
.

In this large meta-analysis of patients with non-metastatic colon cancer (CC), researchers analyzed the effects of diabetes and metformin treatment on recurrence and survival in colon cancer patients

Diabetes (DM) and metastatic colorectal (CRC)Increased colorectal cancer risk and worse prognosis linked to diabetescolorectal cancer colon cancer metformin

Three randomized adjuvant trials were included in this study, with pooled analyses at the patient level
.

All patients had stage II-III colon cancer, underwent resection, and received standard adjuvant fluoropyrimidine and oxaliplatin (± cetuximab)

Survival and recurrence-free rates in patients with and without diabetes

A total of 5922 colon cancer patients were included with a median follow-up of 6.
8 months, of whom 621 (10.
5%) had diabetes at the time of colon cancer diagnosis
.

Among patients with diabetes mellitus, 327 (52.

Colon cancer patients with diabetes had significantly shorter time to recurrence (adjusted hazard ratio [adjHR] 1.

Survival of patients with and without metformin

The time to recurrence (adjHR 1.
28, p=0.
032) and overall survival (adjHR 1.
41, p=0.
003) of colon cancer patients with diabetes who did not receive metformin were also significantly shorter than those without diabetes
.

The time to recurrence (adjHR 1.
28, p=0.
032) and overall survival (adjHR 1.
41, p=0.
003) of colon cancer patients with diabetes who did not receive metformin were also significantly shorter than those without diabetes
.

The time to recurrence (adjHR 1.

Colon cancer patients with diabetes had a shorter time to recurrence and a worse survival prognosis compared with colon cancer patients without diabetes.

Original source:

Christou Niki,Bergen Elisabeth S,Canton Clemence et al.

Impact of diabetes and metformin use on recurrence and outcome in stage II-III colon cancer patients-A pooled analysis of three adjuvant trials